Indeed, recent studies have reported that genetic knock-out of the DYRK1A gene sensitizes CRC cells to topotecan [46], an anti-tumor drug similar to irinotecan in chemical structure and mechanism of action, commonly used to treat ovarian cancer. This evidence concerns the gene DYRK1A and ovarian carcinoma.